All results
14 results
-
9001-303 (ENVISION)
The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is…
- Ages
- N/A - N/A
- Sexes
- Male
-
ANCHORS: UH3
80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of…
- Ages
- 18 Years - 30 Years
- Sexes
- Male
-
EMBARK
The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The…
- Ages
- 4 Years - 7 Years
- Sexes
- Male
-
Edgewise-201 (CANYON)
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was…
- Ages
- 12 Years - 50 Years
- Sexes
- Male
-
Edgewise-210
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…
- Ages
- 4 Years - 9 Years
- Sexes
- Male
-
Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…
- Ages
- 18 Years - N/A
- Sexes
- Male
-
Givinostat Long Term Study
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been…
- Ages
- 7 Years - N/A
- Sexes
- Male
-
High Risk Prostate CA: Less Intense Tx for Low Risk Scores and More Intense Tx for High Risk Scores
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high…
- Ages
- 18 Years - N/A
- Sexes
- Male
-
Magnetic resonance imaging and biomarkers for muscular dystrophy
The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease…
- Ages
- 5 Years - 62 Years
- Sexes
- Male
-
Pfizer Early Stage GT
The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm,…
- Ages
- 2 Years - 3 Years
- Sexes
- Male